Clinical trials: Dual Antiplatelet Therapy
Coronary Disease, Drug Eluting Stent
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
This study is to assess the clinical non-inferiority of 1 month (short-term) vs 6 months (long-term) of dual anti-platelet therapy in patients undergoing percutaneous intervention implanted sirolimus -eluting stent with abluminal…
- Conditions
- Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03287167
- Testing
- 1 month DAPT, 6 months DAPT
- Where
- China
- Volunteers
- 1,720 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Vertebral Artery Stenosis
Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study
This is a prospective, multi-center, registry study exploring the duration of dual antiplatelet therapy (DAPT) after drug-eluting stent(DES) treatment of symptomatic vertebral artery atherosclerotic stenosis.
- Trial name
- M Short DAPT (NCT06683300)
- Testing
- DAPT for 3 months after vertebral artery stenting
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Beijing Tiantan Hospital
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
The aim of this study is to assess the safety and efficacy of the CYP2C19 genotype-guided abbreviated dual antiplatelet therapy (DAPT) strategy versus the un-guided stepwise intensity de-escalation of DAPT strategy in patients…
- Trial name
- GUIDE-HBR (NCT06763744)
- Testing
- P2Y12 antagonist monotherapy, clopidogrel + aspirin
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Samsung Medical Center
Thrombosis, Myocardial Infarction
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
The investigators will be comparing the effects of two different drug treatment strategies, in patients with history of a heart attack, on different markers of bleeding and clotting risk.
- Trial name
- DEFINE CCS (NCT05116995)
- Testing
- Rivaroxaban, Ticagrelor
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Nova Scotia Health Authority
Coronary Artery Disease, CABG
The 10-Year Extended Follow-up of the DACAB Trial
The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial.
- Conditions
- Coronary Artery Disease, CABG, Antiplatelet Therapy of Coronary Artery Bypass
- Trial name
- DACAB-FE-10Y (NCT07480629)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Intracranial Aneurysm
Low Dose Prasugrel vs Clopidogrel for Stenting or Flow Diverter for Unruptured Aneurysm
Low clopidogrel response has been reported in about 5-44% of the total population, which is associated with an increase in thromboembolism. Recently prasugrel drug widely accepted as a good option for these patients.
- Trial name
- NCT05359224
- Testing
- Prasugrel group, Clopidogrel group
- Where
- South Korea
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Gastrointestinal Injury, Ischemic Heart Disease
Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation
Long-term DAPT is recommended after percutaneous coronary intervention (PCI) in patients with coronary artery disease. However, antiplatelet therapy may have adverse consequences, the most common of which is gastrointestinal…
- Trial name
- OPT-PEACE (NCT03198741)
- Testing
- Aspirin + clopidogrel, Clopidogrel monotherapy, Aspirin monotherapy
- Where
- China
- Volunteers
- 783 people
- Sponsor
- Shenyang Northern Hospital
Coronary Artery Disease, High On-treatment Platelet Reactivity (HTPR)
Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)
The goal of this clinical trial is to learn whether a low dose of apixaban, a blood-thinning medicine, changes how active the platelets are in adults with stable coronary artery disease who are already taking aspirin and…
- Trial name
- ACER (NCT07853612)
- Testing
- Apixaban
- Where
- Trinidad and Tobago
- Volunteers
- 16 people
- Sponsor
- The University of The West Indies
Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation.
- Conditions
- Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease
- Trial name
- TAILOR-DAPT (NCT05732701)
- Testing
- Algorithm-guided DAPT duration, Standard-of-care DAPT duration
- Where
- 3 sites in Bosnia and Herzegovina, Italy and 1 more
- Volunteers
- 2,788 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Coronary Artery Ectasia, Acute Coronary Syndromes (ACS)
Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia
Coronary artery ectasia (CAE) is a condition in which a coronary artery becomes abnormally dilated, measuring at least 50% larger than the adjacent normal segment.
- Conditions
- Coronary Artery Ectasia, Acute Coronary Syndromes (ACS), STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
- Trial name
- OVER-TIME II (NCT07511257)
- Testing
- Aspirin 100 mg, Clopidogrel 75 mg, Rivaroxaban 15 mg
- Where
- Mexico
- Volunteers
- 326 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Acute Coronary Syndrome
Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)
1. Objective : To test the safety of 6 month-duration of dual antiplatelet therapy (DAPT) compared to conventional 12-month-or-longer duration after second-generation drug-eluting stent (DES) implantation in patients with acute…
- Trial name
- SMART-DATE (NCT01701453)
- Testing
- P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
- Where
- South Korea
- Volunteers
- 2,712 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease, Percutaneous Coronary Intervention
Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
All patients undergoing elective or sub-acute PCI are screened by MULTIPLATE test for clopidogrel low-responsiveness after receiving 600 mg clopidogrel the day before. A cut off value has previously been established.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes
- Trial name
- TAILOR (NCT01135667)
- Testing
- clopidogrel, Prasugrel 10 mg
- Where
- Denmark
- Volunteers
- 106 people
- Sponsor
- Lene Holmvang
ST Elevation Myocardial Infarction
3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI
To compare the clinical outcomes of dual antiplatelet therapy with aspirin and P2Y12 receptor inhibitor vs. ticagrelor monotherapy at 3 months after PCI in patients with ST-elevation myocardial infarction.
- Trial name
- BULK-STEMI (NCT04570345)
- Testing
- ticagrelor monotherapy, Aspirin with P2Y12 receptor inhibitor
- Where
- South Korea
- Volunteers
- 1,002 people
- Sponsor
- Dong-A University
Ischemic Heart Disease, Coronary Artery Disease
Prospective Registry of Patients Over 75 Years Old Treated With Xience Sierra Stents. Sierra 75 Study
This prospective registry is intended to evaluate the safety and efficacy of the XIENCE Sierra stent.
- Trial name
- SIERRA 75 (NCT03567733)
- Testing
- XIENCE Sierra
- Where
- 44 sites in Portugal, Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundación EPIC
Acute Stroke, Transient Ischemic Attack
Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis
Large-artery stenosis plays an important role in the occurrence of ischemic stroke. The primary purpose of this study is to evaluate the efficacy and safety of intensive antiplatelet therapy versus standard antiplatelet therapy…
- Trial name
- INSPIRES (NCT03635749)
- Testing
- Intensive antiplatelet, Standard antiplatelet, Immediate high-intensity statin
- Where
- 113 sites in China
- Volunteers
- 6,100 people
- Sponsor
- Beijing Tiantan Hospital
High Bleeding Risk Patients, Cardiology
Dual Anti-Platelet Optimized Stent for High Bleeding Risk Patient
High risk of bleeding (HBR) is a determining factor for the duration of dual antiplatelet therapy (DAPT). Recent studies have shown that the use of one-month DAPT is beneficial in terms of ischemic as well as hemorrhagic events…
- Conditions
- High Bleeding Risk Patients, Cardiology, Stent Implantation, DAPT(Dual Antiplatelet Therapy)
- Trial name
- DIOHR (NCT07140133)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- University Hospital, Grenoble
Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR)
Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
Study Purpose Coronary heart disease (CAD) is a leading global cause of death, with Acute Coronary Syndrome (ACS) as its acute and life-threatening subtype.
- Conditions
- Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR), Coronary Artery Disease (CAD)
- Trial name
- NCT07354828
- Where
- China
- Volunteers
- 3,500 people
- Sponsor
- Shenyang Northern Hospital
Coronary Artery Disease, Clopidogrel Resistance
The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models
The study purposed to learn how clopidogrel-based antiplatelet treatment for preventing adverse cardiovascular events after ePCI works in chronic coronary artery disease when guided by personal genetic characteristics for drug…
- Conditions
- Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac Events
- Trial name
- NCT06665919
- Testing
- CYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
- Where
- 4 sites in Georgia
- Volunteers
- 283 people
- Sponsor
- Vistamedi Ltd.
Gastrointestinal Ulcer (Peptic) or Erosion, Anti-Platelet Therapy
Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG
The purpose of this study is to compare the efficacy and safety for 12- vs. 1-month of pantoprazole treatment in preventing dual antiplatelet therapy (DAPT)-related upper gastrointestinal mucosal injury after coronary artery…
- Conditions
- Gastrointestinal Ulcer (Peptic) or Erosion, Anti-Platelet Therapy, Coronary Artery Bypass
- Trial name
- DACAB-GI-2 (NCT03908593)
- Testing
- Pantoprazole
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Ruijin Hospital
STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study
The aim of this study is to determine the prevalence of Helicobacter pylori (Hp) infection in patients with myocardial infarction (MI).
- Trial name
- HELPpilot (NCT04289012)
- Testing
- Helicobacter Pylori screening by UBT
- Where
- 2 sites in Sweden
- Volunteers
- 300 people
- Sponsor
- Karolinska Institutet